Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes
Type II diabetes costs the NHS £8.8 billion a year.
Read More
Tag: Oral semaglutide
Novo’s oral semaglutide hits targets in diabetics with renal impairment
Novo Nordisk says trial data show an oral formulation of its GLP-1 analogue semaglutide provided superior HbA1c and weight reductions versus placebo in people with type II diabetes and renal impairment.
Read More
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
